57 results about "Haemophilus influenzae type" patented technology

The invention discloses a preparation method of Haemophilus influenzae type B polysaccharide-conjugated vaccine. The preparation method is: extract the polysaccharide of Haemophilus influenzae type B, and dissolve PRP polysaccharide to 20 mg / ml with ultrapure water or water for injection at room temperature According to the condition that the mass ratio of PRP and CDAP is 1, CDAP is added and maintained for 1.5 min. Adjust the pH to 9.5 with 0.3M NaOH and maintain it for 3 minutes. Add solid ADH according to the condition that the mass ratio of ADH to PRP polysaccharide is 4:1. Adjust the pH to 9.5 with 0.3M NaOH and maintain it for 1h. 2-8°C, 0.2M NaCl dialysis; B. The dialyzed PRP-AH was mixed with 20mg / ml TT solution at a mass ratio of 1:2. Adjust the pH to 5.0 with 0.1M HCL, then add solid EDAC at a ratio of 10:1 mass ratio between EDAC and PRP, maintain the pH at room temperature at 5.060min, and adjust the pH to 7.5 with 0.3M NaOH for 30min.

A process for detecting Haemophilus influenzae nucleic acid in a sample includes producing an amplification product by amplifying a Haemophilus influenzae nucleotide sequence and measuring the amplification product to detect Haemophilus influenzae in the sample. Some embodiments allow direct serotype determination in a single step assay. Also provided are reagents and methods for detecting and distinguishing Haemophilus influenzae from other infectious agents. A kit is provided for detecting and quantifying Haemophilus influenzae in a sample.

The invention discloses a preparation method of a non-adjuvant Haemophilus influenzae type b conjugate vaccine freeze-drying agent, which includes formulation, mixture preparation and freeze-drying process. In the process of vacuum freeze-sublimation drying in the freeze-drying process to remove free water, the present invention controls the temperature of the bottled material below the eutectic point of free water and bound water to eliminate the aggregation of CRM197 protein; removes free water by desorption and drying in vacuum During the process, the temperature of the bottled material is controlled below the degradation point to eliminate the degradation of the Hib capsule structure, so that the Haemophilus influenzae type b conjugate vaccine freeze-dried agent does not need to add an adjuvant technical solution, which overcomes the protein aggregation existing in the prior art , structural degradation, and the problems and shortcomings of adding adjuvants, the Haemophilus influenzae type b combined vaccine freeze-dried agent has achieved the purpose of eliminating protein aggregation and structural degradation without adding adjuvants.